-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the first day of listing of A-shares has become a hot topic in the market, which has attracted widespread attention
.
According to statistics, 8 of the 19 new stocks listed on the 8 trading days broke on the first day, including 3 pharmaceutical stocks including Chengda Biologics and Corfu Medical.
There was even a tragic loss of 10,000 in the first signing.
The new sentiment can be described as a decline.
To freezing point
.
It is worth mentioning that none of the companies listed in 2020 will break their first day
.
However, there are frequent breaks, is "new" not popular?
.
According to statistics, 8 of the 19 new stocks listed on the 8 trading days broke on the first day, including 3 pharmaceutical stocks including Chengda Biologics and Corfu Medical.
There was even a tragic loss of 10,000 in the first signing.
The new sentiment can be described as a decline.
To freezing point
.
It is worth mentioning that none of the companies listed in 2020 will break their first day
.
However, there are frequent breaks, is "new" not popular?
90% gross profit margin can't hold it! Hundred yuan pharmaceutical stocks broke on the first day of listing, with a loss of more than 10,000 yuan in the first signing
According to statistics, 8 of the 19 new stocks listed on 8 trading days broke on the first day, including 3 pharmaceutical stocks including Chengda Biotech and Corfu Medical
.
Among them, Chengda Biotech’s issue price is as high as 110 yuan, which is the ninth 100-yuan stock this year.
However, the “big meat sign” with high expectations has surprised investors.
On the first day of listing, the market value evaporated by more than 10 billion yuan, with a loss of more than 10,000 yuan in the first lottery
.
.
Among them, Chengda Biotech’s issue price is as high as 110 yuan, which is the ninth 100-yuan stock this year.
However, the “big meat sign” with high expectations has surprised investors.
On the first day of listing, the market value evaporated by more than 10 billion yuan, with a loss of more than 10,000 yuan in the first lottery
.
Statistics show that larger organisms is a subsidiary of Liaoning Cheng Kung University, is a focus on human vaccine development, production and marketing of biotech companies , core products including human rabies vaccine and inactivated JE vaccine
.
A few days ago, Chengda Biotech disclosed its results for the first three quarters of 2021.
Revenue was 1.
735 billion yuan, an increase of 4.
42% year-on-year; net profit was 829 million yuan, a year-on-year decrease of 0.
27%; gross profit margin reached 89.
91%
.
.
A few days ago, Chengda Biotech disclosed its results for the first three quarters of 2021.
Revenue was 1.
735 billion yuan, an increase of 4.
42% year-on-year; net profit was 829 million yuan, a year-on-year decrease of 0.
27%; gross profit margin reached 89.
91%
.
It is worth noting that Chengda Biotech pointed out in the prospectus that the company has a relatively single product structure.
In recent years, core product revenue accounted for more than 90% of total revenue
.
In this regard, Chengda Biotech stated that the company has attached great importance to R&D investment for a long time, relying on its own core technology and R&D capabilities, focusing on the upgrading of traditional vaccines with large market potential and the research and development of innovative vaccines, and is actively planning around the national vaccine supply system.
Promote the development of multi-linked multivalent vaccines and further expand the product portfolio
.
The company has achieved a number of phased results in research and development.
For example, the successful development of the vaccine project under research and the smooth implementation of commercial production will enrich the company's products and is expected to become a new profit growth point
.
In recent years, core product revenue accounted for more than 90% of total revenue
.
In this regard, Chengda Biotech stated that the company has attached great importance to R&D investment for a long time, relying on its own core technology and R&D capabilities, focusing on the upgrading of traditional vaccines with large market potential and the research and development of innovative vaccines, and is actively planning around the national vaccine supply system.
Promote the development of multi-linked multivalent vaccines and further expand the product portfolio
.
The company has achieved a number of phased results in research and development.
For example, the successful development of the vaccine project under research and the smooth implementation of commercial production will enrich the company's products and is expected to become a new profit growth point
.
The TOP10 most profitable pharmaceutical stocks are released! This year only two of over 10 Wan
TOP10 pharmaceutical stocks that have made profits for each Chinese first sign from 2020 to now
Recently, the first-day break of new shares in the A-share market seems to be "normal", but it is still relatively rare to lose more than 10,000 yuan after winning the lottery.
Especially for pharmaceutical stocks, they have always been a "golden ground" for investors
.
According to statistics, the average profit of the 42 pharmaceutical stocks listed in 2020 is more than 40,000 yuan, and the average of the 43 pharmaceutical stocks listed this year is 25,000 yuan
.
Among the TOP10 pharmaceutical stocks, 6 of them gained more than RMB 100,000 in the first-in-one sign.
Among them, Kanghua Biological, Ganli Pharmaceutical, Wantai Biological, and Amec were all listed last year.
This year, only Haoyuan Pharmaceuticals and Yimeike Alice China
.
Especially for pharmaceutical stocks, they have always been a "golden ground" for investors
.
According to statistics, the average profit of the 42 pharmaceutical stocks listed in 2020 is more than 40,000 yuan, and the average of the 43 pharmaceutical stocks listed this year is 25,000 yuan
.
Among the TOP10 pharmaceutical stocks, 6 of them gained more than RMB 100,000 in the first-in-one sign.
Among them, Kanghua Biological, Ganli Pharmaceutical, Wantai Biological, and Amec were all listed last year.
This year, only Haoyuan Pharmaceuticals and Yimeike Alice China
.
Haoyuan Pharmaceutical is a platform-based high-tech enterprise focusing on small molecule drug research and development services and industrial applications.
Its main business includes the research and development of molecular building blocks and tool compounds in the field of small molecule drug discovery, as well as small molecule drug raw materials and intermediates.
The process development and production technology improvement of the company provide global pharmaceutical companies and scientific research institutions with related products and technical services from drug discovery to the large-scale production of APIs and pharmaceutical intermediates
.
In the first three quarters of this year, the company's revenue was 696 million yuan, a year-on-year increase of 68.
62%; net profit was 144 million yuan, a year-on-year increase of 103.
78%.
Both revenue and net profit have exceeded the full year of 2020
.
In the future, the company will continue to explore the direction of product expansion in new areas, optimize the company's product structure, and increase profitability growth points
.
Its main business includes the research and development of molecular building blocks and tool compounds in the field of small molecule drug discovery, as well as small molecule drug raw materials and intermediates.
The process development and production technology improvement of the company provide global pharmaceutical companies and scientific research institutions with related products and technical services from drug discovery to the large-scale production of APIs and pharmaceutical intermediates
.
In the first three quarters of this year, the company's revenue was 696 million yuan, a year-on-year increase of 68.
62%; net profit was 144 million yuan, a year-on-year increase of 103.
78%.
Both revenue and net profit have exceeded the full year of 2020
.
In the future, the company will continue to explore the direction of product expansion in new areas, optimize the company's product structure, and increase profitability growth points
.
Yiqiao Shenzhou is a biotechnology company engaged in the development, production, sales and technical services of biological reagents.
Its main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services
.
The company has attracted much attention with its "most expensive" new shares.
The issue price was as high as RMB 292.
92.
It opened at RMB 599.
90 on the first day of listing, which was twice the issue price
.
In 2020, the company’s revenue was 1.
596 billion yuan, a year-on-year increase of more than 780%.
Among them, the new crown virus-related product revenue accounted for more than 80%; net profit was 1.
128 billion yuan, a year-on-year increase of 2969.
90%; in the first three quarters of this year, revenue and net Profits have fallen year-on-year
.
Yiqiao Shenzhou stated that since the outbreak of the new crown epidemic, the biological reagent products developed by the company have been purchased in large quantities by domestic and foreign customers , and its operating performance has grown rapidly
.
Although the revenue of non-epidemic virus-related products is expected to maintain growth, due to the large uncertainty in the market demand for epidemic virus-related products, the company's overall operating income and profit levels are at risk of decline in 2021
.
Its main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services
.
The company has attracted much attention with its "most expensive" new shares.
The issue price was as high as RMB 292.
92.
It opened at RMB 599.
90 on the first day of listing, which was twice the issue price
.
In 2020, the company’s revenue was 1.
596 billion yuan, a year-on-year increase of more than 780%.
Among them, the new crown virus-related product revenue accounted for more than 80%; net profit was 1.
128 billion yuan, a year-on-year increase of 2969.
90%; in the first three quarters of this year, revenue and net Profits have fallen year-on-year
.
Yiqiao Shenzhou stated that since the outbreak of the new crown epidemic, the biological reagent products developed by the company have been purchased in large quantities by domestic and foreign customers , and its operating performance has grown rapidly
.
Although the revenue of non-epidemic virus-related products is expected to maintain growth, due to the large uncertainty in the market demand for epidemic virus-related products, the company's overall operating income and profit levels are at risk of decline in 2021
.
Frequent breaks! Isn't "new hitting" fragrant anymore?
In recent years, the China Securities Regulatory Commission and other regulatory authorities have frequently issued new policies.
Since the implementation of the registration system, it is not uncommon for new shares to be broken after listing, but it is rare for them to break on the first day of listing
.
According to statistics, since the opening of the A-share market, there have been seven rounds of new shares breaking.
In the past two years, only two companies have broken their shares on the first day of listing, both of which occurred in 2019.
None of the companies listed in 2020 have broken their shares on the first day
.
There are many reasons for the IPO break, including factors such as policies, market sentiment, and the company's own fundamentals
.
The recent "hairbreaking wave" is on the one hand related to the implementation of the new price inquiry regulations, and on the other hand, it is caused by the influence of market sentiment
.
Since the implementation of the registration system, it is not uncommon for new shares to be broken after listing, but it is rare for them to break on the first day of listing
.
According to statistics, since the opening of the A-share market, there have been seven rounds of new shares breaking.
In the past two years, only two companies have broken their shares on the first day of listing, both of which occurred in 2019.
None of the companies listed in 2020 have broken their shares on the first day
.
There are many reasons for the IPO break, including factors such as policies, market sentiment, and the company's own fundamentals
.
The recent "hairbreaking wave" is on the one hand related to the implementation of the new price inquiry regulations, and on the other hand, it is caused by the influence of market sentiment
.
In fact, the lower the issue price is, the greater the stock price will rise after listing.
This low-risk, high-yield investment method allows institutions to make a lot of money
.
The relevant person in charge of the China Securities Regulatory Commission has said that some offline investors focus on strategy rather than research, and “group quotations” for Bo’s finalists will interfere with the issuance order
.
This low-risk, high-yield investment method allows institutions to make a lot of money
.
The relevant person in charge of the China Securities Regulatory Commission has said that some offline investors focus on strategy rather than research, and “group quotations” for Bo’s finalists will interfere with the issuance order
.
On September 18 this year, the Shanghai Stock Exchange issued the newly revised "Shanghai Stock Exchange Science and Technology Innovation Board Stock Issuance and Underwriting Implementation Measures" and "Shanghai Stock Exchange Science and Technology Innovation Board Issuance and Underwriting Rules Application Guidelines No.
1-Initial Public Offering of Shares On the same day, the Shenzhen Stock Exchange issued a newly revised " Implementation Rules for the Initial Public Offering and Underwriting of Securities on the Growth Enterprise Market
.
" Recently, the Securities Association of China issued an announcement to sign the "Memorandum of Understanding on Strengthening the Supervision of Offline Price Inquiries for New Shares under the Registration System" with the Shanghai Stock Exchange and the Shenzhen Stock Exchange to jointly strengthen the supervision of the quotation behavior of offline investors under the registration system for initial public offerings
.
1-Initial Public Offering of Shares On the same day, the Shenzhen Stock Exchange issued a newly revised " Implementation Rules for the Initial Public Offering and Underwriting of Securities on the Growth Enterprise Market
.
" Recently, the Securities Association of China issued an announcement to sign the "Memorandum of Understanding on Strengthening the Supervision of Offline Price Inquiries for New Shares under the Registration System" with the Shanghai Stock Exchange and the Shenzhen Stock Exchange to jointly strengthen the supervision of the quotation behavior of offline investors under the registration system for initial public offerings
.
As one of the key links in the reform of the registration system, from the perspective of the effect of the implementation of the policy, the increase in the initial stage of the company's listing has declined, the return of new shares has declined, and even the break is occurred, indicating that the new regulations have gradually moved the pricing of new shares to market
.
On the other hand, this will force institutions and investors to increase their research on new stocks, further understand and recognize the company’s fundamentals such as business strategy, product structure, and R&D investment, and to a certain extent curb “closed eyes”.
"The unreasonable behavior of making money by playing new shares has gradually transformed into a judgment on the true value of new stocks, allowing the market to return to rationalization
.
.
On the other hand, this will force institutions and investors to increase their research on new stocks, further understand and recognize the company’s fundamentals such as business strategy, product structure, and R&D investment, and to a certain extent curb “closed eyes”.
"The unreasonable behavior of making money by playing new shares has gradually transformed into a judgment on the true value of new stocks, allowing the market to return to rationalization
.
Source: Oriental Fortune Network
If there is any omission, please correct me!
Recently, the first day of listing of A-shares has become a hot topic in the market, which has attracted widespread attention
.
According to statistics, 8 of the 19 new stocks listed on the 8 trading days broke on the first day, including 3 pharmaceutical stocks including Chengda Biologics and Corfu Medical.
There was even a tragic loss of 10,000 in the first signing.
The new sentiment can be described as a decline.
To freezing point
.
It is worth mentioning that none of the companies listed in 2020 will break their first day
.
However, there are frequent breaks, is "new" not popular?
.
According to statistics, 8 of the 19 new stocks listed on the 8 trading days broke on the first day, including 3 pharmaceutical stocks including Chengda Biologics and Corfu Medical.
There was even a tragic loss of 10,000 in the first signing.
The new sentiment can be described as a decline.
To freezing point
.
It is worth mentioning that none of the companies listed in 2020 will break their first day
.
However, there are frequent breaks, is "new" not popular?
90% gross profit margin can't hold it! Hundred yuan pharmaceutical stocks broke on the first day of listing, with a loss of more than 10,000 yuan in the first signing
According to statistics, 8 of the 19 new stocks listed on 8 trading days broke on the first day, including 3 pharmaceutical stocks including Chengda Biotech and Corfu Medical
.
Among them, Chengda Biotech’s issue price is as high as 110 yuan, which is the ninth 100-yuan stock this year.
However, the “big meat sign” with high expectations has surprised investors.
On the first day of listing, the market value evaporated by more than 10 billion yuan, with a loss of more than 10,000 yuan in the first lottery
.
.
Among them, Chengda Biotech’s issue price is as high as 110 yuan, which is the ninth 100-yuan stock this year.
However, the “big meat sign” with high expectations has surprised investors.
On the first day of listing, the market value evaporated by more than 10 billion yuan, with a loss of more than 10,000 yuan in the first lottery
.
Statistics show that larger organisms is a subsidiary of Liaoning Cheng Kung University, is a focus on human vaccine development, production and marketing of biotech companies , core products including human rabies vaccine and inactivated JE vaccine
.
A few days ago, Chengda Biotech disclosed its results for the first three quarters of 2021.
Revenue was 1.
735 billion yuan, an increase of 4.
42% year-on-year; net profit was 829 million yuan, a year-on-year decrease of 0.
27%; gross profit margin reached 89.
91%
.
.
A few days ago, Chengda Biotech disclosed its results for the first three quarters of 2021.
Revenue was 1.
735 billion yuan, an increase of 4.
42% year-on-year; net profit was 829 million yuan, a year-on-year decrease of 0.
27%; gross profit margin reached 89.
91%
.
It is worth noting that Chengda Biotech pointed out in the prospectus that the company has a relatively single product structure.
In recent years, core product revenue accounted for more than 90% of total revenue
.
In this regard, Chengda Biotech stated that the company has attached great importance to R&D investment for a long time, relying on its own core technology and R&D capabilities, focusing on the upgrading of traditional vaccines with large market potential and the research and development of innovative vaccines, and is actively planning around the national vaccine supply system.
Promote the development of multi-linked multivalent vaccines and further expand the product portfolio
.
The company has achieved a number of phased results in research and development.
For example, the successful development of the vaccine project under research and the smooth implementation of commercial production will enrich the company's products and is expected to become a new profit growth point
.
In recent years, core product revenue accounted for more than 90% of total revenue
.
In this regard, Chengda Biotech stated that the company has attached great importance to R&D investment for a long time, relying on its own core technology and R&D capabilities, focusing on the upgrading of traditional vaccines with large market potential and the research and development of innovative vaccines, and is actively planning around the national vaccine supply system.
Promote the development of multi-linked multivalent vaccines and further expand the product portfolio
.
The company has achieved a number of phased results in research and development.
For example, the successful development of the vaccine project under research and the smooth implementation of commercial production will enrich the company's products and is expected to become a new profit growth point
.
The TOP10 most profitable pharmaceutical stocks are released! This year only two of over 10 Wan
TOP10 pharmaceutical stocks that have made profits for each Chinese first sign from 2020 to now
Recently, the first-day break of new shares in the A-share market seems to be "normal", but it is still relatively rare to lose more than 10,000 yuan after winning the lottery.
Especially for pharmaceutical stocks, they have always been a "golden ground" for investors
.
According to statistics, the average profit of the 42 pharmaceutical stocks listed in 2020 is more than 40,000 yuan, and the average of the 43 pharmaceutical stocks listed this year is 25,000 yuan
.
Among the TOP10 pharmaceutical stocks, 6 of them gained more than RMB 100,000 in the first-in-one sign.
Among them, Kanghua Biological, Ganli Pharmaceutical, Wantai Biological, and Amec were all listed last year.
This year, only Haoyuan Pharmaceuticals and Yimeike Alice China
.
Especially for pharmaceutical stocks, they have always been a "golden ground" for investors
.
According to statistics, the average profit of the 42 pharmaceutical stocks listed in 2020 is more than 40,000 yuan, and the average of the 43 pharmaceutical stocks listed this year is 25,000 yuan
.
Among the TOP10 pharmaceutical stocks, 6 of them gained more than RMB 100,000 in the first-in-one sign.
Among them, Kanghua Biological, Ganli Pharmaceutical, Wantai Biological, and Amec were all listed last year.
This year, only Haoyuan Pharmaceuticals and Yimeike Alice China
.
Haoyuan Pharmaceutical is a platform-based high-tech enterprise focusing on small molecule drug research and development services and industrial applications.
Its main business includes the research and development of molecular building blocks and tool compounds in the field of small molecule drug discovery, as well as small molecule drug raw materials and intermediates.
The process development and production technology improvement of the company provide global pharmaceutical companies and scientific research institutions with related products and technical services from drug discovery to the large-scale production of APIs and pharmaceutical intermediates
.
In the first three quarters of this year, the company's revenue was 696 million yuan, a year-on-year increase of 68.
62%; net profit was 144 million yuan, a year-on-year increase of 103.
78%.
Both revenue and net profit have exceeded the full year of 2020
.
In the future, the company will continue to explore the direction of product expansion in new areas, optimize the company's product structure, and increase profitability growth points
.
Its main business includes the research and development of molecular building blocks and tool compounds in the field of small molecule drug discovery, as well as small molecule drug raw materials and intermediates.
The process development and production technology improvement of the company provide global pharmaceutical companies and scientific research institutions with related products and technical services from drug discovery to the large-scale production of APIs and pharmaceutical intermediates
.
In the first three quarters of this year, the company's revenue was 696 million yuan, a year-on-year increase of 68.
62%; net profit was 144 million yuan, a year-on-year increase of 103.
78%.
Both revenue and net profit have exceeded the full year of 2020
.
In the future, the company will continue to explore the direction of product expansion in new areas, optimize the company's product structure, and increase profitability growth points
.
Yiqiao Shenzhou is a biotechnology company engaged in the development, production, sales and technical services of biological reagents.
Its main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services
.
The company has attracted much attention with its "most expensive" new shares.
The issue price was as high as RMB 292.
92.
It opened at RMB 599.
90 on the first day of listing, which was twice the issue price
.
In 2020, the company’s revenue was 1.
596 billion yuan, a year-on-year increase of more than 780%.
Among them, the new crown virus-related product revenue accounted for more than 80%; net profit was 1.
128 billion yuan, a year-on-year increase of 2969.
90%; in the first three quarters of this year, revenue and net Profits have fallen year-on-year
.
Yiqiao Shenzhou stated that since the outbreak of the new crown epidemic, the biological reagent products developed by the company have been purchased in large quantities by domestic and foreign customers , and its operating performance has grown rapidly
.
Although the revenue of non-epidemic virus-related products is expected to maintain growth, due to the large uncertainty in the market demand for epidemic virus-related products, the company's overall operating income and profit levels are at risk of decline in 2021
.
Its main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services
.
The company has attracted much attention with its "most expensive" new shares.
The issue price was as high as RMB 292.
92.
It opened at RMB 599.
90 on the first day of listing, which was twice the issue price
.
In 2020, the company’s revenue was 1.
596 billion yuan, a year-on-year increase of more than 780%.
Among them, the new crown virus-related product revenue accounted for more than 80%; net profit was 1.
128 billion yuan, a year-on-year increase of 2969.
90%; in the first three quarters of this year, revenue and net Profits have fallen year-on-year
.
Yiqiao Shenzhou stated that since the outbreak of the new crown epidemic, the biological reagent products developed by the company have been purchased in large quantities by domestic and foreign customers , and its operating performance has grown rapidly
.
Although the revenue of non-epidemic virus-related products is expected to maintain growth, due to the large uncertainty in the market demand for epidemic virus-related products, the company's overall operating income and profit levels are at risk of decline in 2021
.
Frequent breaks! Isn't "new hitting" fragrant anymore?
In recent years, the China Securities Regulatory Commission and other regulatory authorities have frequently issued new policies.
Since the implementation of the registration system, it is not uncommon for new shares to be broken after listing, but it is rare for them to break on the first day of listing
.
According to statistics, since the opening of the A-share market, there have been seven rounds of new shares breaking.
In the past two years, only two companies have broken their shares on the first day of listing, both of which occurred in 2019.
None of the companies listed in 2020 have broken their shares on the first day
.
There are many reasons for the IPO break, including factors such as policies, market sentiment, and the company's own fundamentals
.
The recent "hairbreaking wave" is on the one hand related to the implementation of the new price inquiry regulations, and on the other hand, it is caused by the influence of market sentiment
.
Since the implementation of the registration system, it is not uncommon for new shares to be broken after listing, but it is rare for them to break on the first day of listing
.
According to statistics, since the opening of the A-share market, there have been seven rounds of new shares breaking.
In the past two years, only two companies have broken their shares on the first day of listing, both of which occurred in 2019.
None of the companies listed in 2020 have broken their shares on the first day
.
There are many reasons for the IPO break, including factors such as policies, market sentiment, and the company's own fundamentals
.
The recent "hairbreaking wave" is on the one hand related to the implementation of the new price inquiry regulations, and on the other hand, it is caused by the influence of market sentiment
.
In fact, the lower the issue price is, the greater the stock price will rise after listing.
This low-risk, high-yield investment method allows institutions to make a lot of money
.
The relevant person in charge of the China Securities Regulatory Commission has said that some offline investors focus on strategy rather than research, and “group quotations” for Bo’s finalists will interfere with the issuance order
.
This low-risk, high-yield investment method allows institutions to make a lot of money
.
The relevant person in charge of the China Securities Regulatory Commission has said that some offline investors focus on strategy rather than research, and “group quotations” for Bo’s finalists will interfere with the issuance order
.
On September 18 this year, the Shanghai Stock Exchange issued the newly revised "Shanghai Stock Exchange Science and Technology Innovation Board Stock Issuance and Underwriting Implementation Measures" and "Shanghai Stock Exchange Science and Technology Innovation Board Issuance and Underwriting Rules Application Guidelines No.
1-Initial Public Offering of Shares On the same day, the Shenzhen Stock Exchange issued a newly revised " Implementation Rules for the Initial Public Offering and Underwriting of Securities on the Growth Enterprise Market
.
" Recently, the Securities Association of China issued an announcement to sign the "Memorandum of Understanding on Strengthening the Supervision of Offline Price Inquiries for New Shares under the Registration System" with the Shanghai Stock Exchange and the Shenzhen Stock Exchange to jointly strengthen the supervision of the quotation behavior of offline investors under the registration system for initial public offerings
.
1-Initial Public Offering of Shares On the same day, the Shenzhen Stock Exchange issued a newly revised " Implementation Rules for the Initial Public Offering and Underwriting of Securities on the Growth Enterprise Market
.
" Recently, the Securities Association of China issued an announcement to sign the "Memorandum of Understanding on Strengthening the Supervision of Offline Price Inquiries for New Shares under the Registration System" with the Shanghai Stock Exchange and the Shenzhen Stock Exchange to jointly strengthen the supervision of the quotation behavior of offline investors under the registration system for initial public offerings
.
As one of the key links in the reform of the registration system, from the perspective of the effect of the implementation of the policy, the increase in the initial stage of the company's listing has declined, the return of new shares has declined, and even the break is occurred, indicating that the new regulations have gradually moved the pricing of new shares to market
.
On the other hand, this will force institutions and investors to increase their research on new stocks, further understand and recognize the company’s fundamentals such as business strategy, product structure, and R&D investment, and to a certain extent curb “closed eyes”.
"The unreasonable behavior of making money by playing new shares has gradually transformed into a judgment on the true value of new stocks, allowing the market to return to rationalization
.
.
On the other hand, this will force institutions and investors to increase their research on new stocks, further understand and recognize the company’s fundamentals such as business strategy, product structure, and R&D investment, and to a certain extent curb “closed eyes”.
"The unreasonable behavior of making money by playing new shares has gradually transformed into a judgment on the true value of new stocks, allowing the market to return to rationalization
.
Source: Oriental Fortune Network
If there is any omission, please correct me!
Recently, the first day of listing of A-shares has become a hot topic in the market, which has attracted widespread attention
.
According to statistics, 8 of the 19 new stocks listed on the 8 trading days broke on the first day, including 3 pharmaceutical stocks including Chengda Biologics and Corfu Medical.
There was even a tragic loss of 10,000 in the first signing.
The new sentiment can be described as a decline.
To freezing point
.
It is worth mentioning that none of the companies listed in 2020 will break their first day
.
However, there are frequent breaks, is "new" not popular?
.
According to statistics, 8 of the 19 new stocks listed on the 8 trading days broke on the first day, including 3 pharmaceutical stocks including Chengda Biologics and Corfu Medical.
There was even a tragic loss of 10,000 in the first signing.
The new sentiment can be described as a decline.
To freezing point
.
It is worth mentioning that none of the companies listed in 2020 will break their first day
.
However, there are frequent breaks, is "new" not popular?
90% gross profit margin can't hold it! Hundred yuan pharmaceutical stocks broke on the first day of listing, with a loss of more than 10,000 yuan in the first signing
90% gross profit margin can't hold it! Hundred Yuan Pharmaceutical stocks listed on the first day of break, the loss of over 10,000 yuan a sign Pharmaceutical Medicine According to statistics, 8 of the 19 new stocks listed on 8 trading days broke on the first day, including 3 pharmaceutical stocks including Chengda Biotech and Corfu Medical
.
Among them, Chengda Biotech’s issue price is as high as 110 yuan, which is the ninth 100-yuan stock this year.
However, the “big meat sign” with high expectations has surprised investors.
On the first day of listing, the market value evaporated by more than 10 billion yuan, with a loss of more than 10,000 yuan in the first lottery
.
.
Among them, Chengda Biotech’s issue price is as high as 110 yuan, which is the ninth 100-yuan stock this year.
However, the “big meat sign” with high expectations has surprised investors.
On the first day of listing, the market value evaporated by more than 10 billion yuan, with a loss of more than 10,000 yuan in the first lottery
.
Statistics show that larger organisms is a subsidiary of Liaoning Cheng Kung University, is a focus on human vaccine development, production and marketing of biotech companies , core products including human rabies vaccine and inactivated JE vaccine
.
A few days ago, Chengda Biotech disclosed its results for the first three quarters of 2021.
Revenue was 1.
735 billion yuan, an increase of 4.
42% year-on-year; net profit was 829 million yuan, a year-on-year decrease of 0.
27%; gross profit margin reached 89.
91%
.
Enterprise business enterprise.
A few days ago, Chengda Biotech disclosed its results for the first three quarters of 2021.
Revenue was 1.
735 billion yuan, an increase of 4.
42% year-on-year; net profit was 829 million yuan, a year-on-year decrease of 0.
27%; gross profit margin reached 89.
91%
.
It is worth noting that Chengda Biotech pointed out in the prospectus that the company has a relatively single product structure.
In recent years, core product revenue accounted for more than 90% of total revenue
.
In this regard, Chengda Biotech stated that the company has attached great importance to R&D investment for a long time, relying on its own core technology and R&D capabilities, focusing on the upgrading of traditional vaccines with large market potential and the research and development of innovative vaccines, and is actively planning around the national vaccine supply system.
Promote the development of multi-linked multivalent vaccines and further expand the product portfolio
.
The company has achieved a number of phased results in research and development.
For example, the successful development of the vaccine project under research and the smooth implementation of commercial production will enrich the company's products and is expected to become a new profit growth point
.
In recent years, core product revenue accounted for more than 90% of total revenue
.
In this regard, Chengda Biotech stated that the company has attached great importance to R&D investment for a long time, relying on its own core technology and R&D capabilities, focusing on the upgrading of traditional vaccines with large market potential and the research and development of innovative vaccines, and is actively planning around the national vaccine supply system.
Promote the development of multi-linked multivalent vaccines and further expand the product portfolio
.
The company has achieved a number of phased results in research and development.
For example, the successful development of the vaccine project under research and the smooth implementation of commercial production will enrich the company's products and is expected to become a new profit growth point
.
The TOP10 most profitable pharmaceutical stocks are released! This year only two of over 10 Wan
The TOP10 most profitable pharmaceutical stocks are released! This year only two of over 10 Wan TOP10 pharmaceutical stocks that have made profits for each Chinese first sign from 2020 to now
Recently, the first-day break of new shares in the A-share market seems to be "normal", but it is still relatively rare to lose more than 10,000 yuan after winning the lottery.
Especially for pharmaceutical stocks, they have always been a "golden ground" for investors
.
According to statistics, the average profit of the 42 pharmaceutical stocks listed in 2020 is more than 40,000 yuan, and the average of the 43 pharmaceutical stocks listed this year is 25,000 yuan
.
Among the TOP10 pharmaceutical stocks, 6 of them gained more than RMB 100,000 in the first-in-one sign.
Among them, Kanghua Biological, Ganli Pharmaceutical, Wantai Biological, and Amec were all listed last year.
This year, only Haoyuan Pharmaceuticals and Yimeike Alice China
.
Especially for pharmaceutical stocks, they have always been a "golden ground" for investors
.
According to statistics, the average profit of the 42 pharmaceutical stocks listed in 2020 is more than 40,000 yuan, and the average of the 43 pharmaceutical stocks listed this year is 25,000 yuan
.
Among the TOP10 pharmaceutical stocks, 6 of them gained more than RMB 100,000 in the first-in-one sign.
Among them, Kanghua Biological, Ganli Pharmaceutical, Wantai Biological, and Amec were all listed last year.
This year, only Haoyuan Pharmaceuticals and Yimeike Alice China
.
Haoyuan Pharmaceutical is a platform-based high-tech enterprise focusing on small molecule drug research and development services and industrial applications.
Its main business includes the research and development of molecular building blocks and tool compounds in the field of small molecule drug discovery, as well as small molecule drug raw materials and intermediates.
The process development and production technology improvement of the company provide global pharmaceutical companies and scientific research institutions with related products and technical services from drug discovery to the large-scale production of APIs and pharmaceutical intermediates
.
In the first three quarters of this year, the company's revenue was 696 million yuan, a year-on-year increase of 68.
62%; net profit was 144 million yuan, a year-on-year increase of 103.
78%.
Both revenue and net profit have exceeded the full year of 2020
.
In the future, the company will continue to explore the direction of product expansion in new areas, optimize the company's product structure, and increase profitability growth points
.
Its main business includes the research and development of molecular building blocks and tool compounds in the field of small molecule drug discovery, as well as small molecule drug raw materials and intermediates.
The process development and production technology improvement of the company provide global pharmaceutical companies and scientific research institutions with related products and technical services from drug discovery to the large-scale production of APIs and pharmaceutical intermediates
.
In the first three quarters of this year, the company's revenue was 696 million yuan, a year-on-year increase of 68.
62%; net profit was 144 million yuan, a year-on-year increase of 103.
78%.
Both revenue and net profit have exceeded the full year of 2020
.
In the future, the company will continue to explore the direction of product expansion in new areas, optimize the company's product structure, and increase profitability growth points
.
Yiqiao Shenzhou is a biotechnology company engaged in the development, production, sales and technical services of biological reagents.
Its main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services
.
The company has attracted much attention with its "most expensive" new shares.
The issue price was as high as RMB 292.
92.
It opened at RMB 599.
90 on the first day of listing, which was twice the issue price
.
In 2020, the company’s revenue was 1.
596 billion yuan, a year-on-year increase of more than 780%.
Among them, the new crown virus-related product revenue accounted for more than 80%; net profit was 1.
128 billion yuan, a year-on-year increase of 2969.
90%; in the first three quarters of this year, revenue and net Profits have fallen year-on-year
.
Yiqiao Shenzhou stated that since the outbreak of the new crown epidemic, the biological reagent products developed by the company have been purchased in large quantities by domestic and foreign customers , and its operating performance has grown rapidly
.
Although the revenue of non-epidemic virus-related products is expected to maintain growth, due to the large uncertainty in the market demand for epidemic virus-related products, the company's overall operating income and profit levels are at risk of decline in 2021
.
Procurement Procurement ProcurementIts main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services
.
The company has attracted much attention with its "most expensive" new shares.
The issue price was as high as RMB 292.
92.
It opened at RMB 599.
90 on the first day of listing, which was twice the issue price
.
In 2020, the company’s revenue was 1.
596 billion yuan, a year-on-year increase of more than 780%.
Among them, the new crown virus-related product revenue accounted for more than 80%; net profit was 1.
128 billion yuan, a year-on-year increase of 2969.
90%; in the first three quarters of this year, revenue and net Profits have fallen year-on-year
.
Yiqiao Shenzhou stated that since the outbreak of the new crown epidemic, the biological reagent products developed by the company have been purchased in large quantities by domestic and foreign customers , and its operating performance has grown rapidly
.
Although the revenue of non-epidemic virus-related products is expected to maintain growth, due to the large uncertainty in the market demand for epidemic virus-related products, the company's overall operating income and profit levels are at risk of decline in 2021
.
Frequent breaks! Isn't "new hitting" fragrant anymore?
Frequent breaks! Isn't "new hitting" fragrant anymore? In recent years, the China Securities Regulatory Commission and other regulatory authorities have frequently issued new policies.
Since the implementation of the registration system, it is not uncommon for new shares to be broken after listing, but it is rare for them to break on the first day of listing
.
According to statistics, since the opening of the A-share market, there have been seven rounds of new shares breaking.
In the past two years, only two companies have broken their shares on the first day of listing, both of which occurred in 2019.
None of the companies listed in 2020 have broken their shares on the first day
.
There are many reasons for the IPO break, including factors such as policies, market sentiment, and the company's own fundamentals
.
The recent "hairbreaking wave" is on the one hand related to the implementation of the new price inquiry regulations, and on the other hand, it is caused by the influence of market sentiment
.
Since the implementation of the registration system, it is not uncommon for new shares to be broken after listing, but it is rare for them to break on the first day of listing
.
According to statistics, since the opening of the A-share market, there have been seven rounds of new shares breaking.
In the past two years, only two companies have broken their shares on the first day of listing, both of which occurred in 2019.
None of the companies listed in 2020 have broken their shares on the first day
.
There are many reasons for the IPO break, including factors such as policies, market sentiment, and the company's own fundamentals
.
The recent "hairbreaking wave" is on the one hand related to the implementation of the new price inquiry regulations, and on the other hand, it is caused by the influence of market sentiment
.
In fact, the lower the issue price is, the greater the stock price will rise after listing.
This low-risk, high-yield investment method allows institutions to make a lot of money
.
The relevant person in charge of the China Securities Regulatory Commission has said that some offline investors focus on strategy rather than research, and “group quotations” for Bo’s finalists will interfere with the issuance order
.
This low-risk, high-yield investment method allows institutions to make a lot of money
.
The relevant person in charge of the China Securities Regulatory Commission has said that some offline investors focus on strategy rather than research, and “group quotations” for Bo’s finalists will interfere with the issuance order
.
On September 18 this year, the Shanghai Stock Exchange issued the newly revised "Shanghai Stock Exchange Science and Technology Innovation Board Stock Issuance and Underwriting Implementation Measures" and "Shanghai Stock Exchange Science and Technology Innovation Board Issuance and Underwriting Rules Application Guidelines No.
1-Initial Public Offering of Shares On the same day, the Shenzhen Stock Exchange issued a newly revised " Implementation Rules for the Initial Public Offering and Underwriting of Securities on the Growth Enterprise Market
.
" Recently, the Securities Association of China issued an announcement to sign the "Memorandum of Understanding on Strengthening the Supervision of Offline Price Inquiries for New Shares under the Registration System" with the Shanghai Stock Exchange and the Shenzhen Stock Exchange to jointly strengthen the supervision of the quotation behavior of offline investors under the registration system for initial public offerings
.
Venture Venture Venture1-Initial Public Offering of Shares On the same day, the Shenzhen Stock Exchange issued a newly revised " Implementation Rules for the Initial Public Offering and Underwriting of Securities on the Growth Enterprise Market
.
" Recently, the Securities Association of China issued an announcement to sign the "Memorandum of Understanding on Strengthening the Supervision of Offline Price Inquiries for New Shares under the Registration System" with the Shanghai Stock Exchange and the Shenzhen Stock Exchange to jointly strengthen the supervision of the quotation behavior of offline investors under the registration system for initial public offerings
.
As one of the key links in the reform of the registration system, from the perspective of the effect of the implementation of the policy, the increase in the initial stage of the company's listing has declined, the return of new shares has declined, and even the break is occurred, indicating that the new regulations have gradually moved the pricing of new shares to market
.
On the other hand, this will force institutions and investors to increase their research on new stocks, further understand and recognize the company’s fundamentals such as business strategy, product structure, and R&D investment, and to a certain extent curb “closed eyes”.
"The unreasonable behavior of making money by playing new shares has gradually transformed into a judgment on the true value of new stocks, allowing the market to return to rationalization
.
.
On the other hand, this will force institutions and investors to increase their research on new stocks, further understand and recognize the company’s fundamentals such as business strategy, product structure, and R&D investment, and to a certain extent curb “closed eyes”.
"The unreasonable behavior of making money by playing new shares has gradually transformed into a judgment on the true value of new stocks, allowing the market to return to rationalization
.
Source: Oriental Fortune Network
If there is any omission, please correct me!
